The Motley Fool: Roche Holding Ltd Is Betting Billions on This New Blockbuster

Roche (NASDAQOTH: RHHBY  ) rarely does expensive early stage deals, relying instead upon its deep proprietary pipeline of oncology drug candidates. So when the company commits itself to $725 million upfront and $1 billion more in milestones (to say nothing of the hundreds of millions that will be required for clinical trials) for a new cancer drug approach, investors would do well to pay attention. When that new approach concerns breast cancer, an area where Roche is particularly strong, it's all the more interesting.

Continue here:
Roche Holding Ltd Is Betting Billions on This New Blockbuster

Seeking Alpha: Johnson & Johnson And Aragon May Have Medivation Feeling Sick

The already-successful new prostate cancer drug Zytiga is not solely responsible for turning around the fortunes of Johnson & Johnson's (JNJ) once-lackluster drug business, but it has certainly played an important role. Johnson & Johnson is now doubling-down on that success, acquiring privately-held Aragon Pharmaceuticals in a $1 billion deal that could represent a major headache for prime prostate cancer drug rival Medivation (MDVN). Although Medivation is likely to have several more years before it has to worry about Aragon's drug, this is very clearly a shot across the bow from a well-armed rival with deep pockets.

Please follow this link for more:
Johnson & Johnson And Aragon May Have Medivation Feeling Sick